Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Cipla COO On Joining The Revolution In Manufacturing

Tue, 04/09/2019 - 1:06pm

Cipla’s global COO Dr R Ananthanarayanan tells Scrip how the company is rethinking and refining its manufacturing operations in the...

      Related Stories 

US FDA Filing Mistake For Fintepla Dents Zogenix

Tue, 04/09/2019 - 8:34am

Zogenix seems only to have itself to blame for an unexpected refusal to file letter from the US agency for...

      Related Stories 

ViiV's Dovato: Treatment-Naive HIV Is Earmarked For The "Complete Regimen"

Tue, 04/09/2019 - 8:29am

The first approval in the US of a once-daily single-tablet, two-drug regimen for treatment-naive HIV from the HIV/AIDS therapy specialist...

      Related Stories 

Missed BEAT Removes Tough Sell For United Therapeutics

Tue, 04/09/2019 - 5:43am

The Phase III failure of esuberaprost combined with Tyvaso in pulmonary arterial hypertension has prompted United Therapeutics to stop developing...

      Related Stories 

Dainippon Pursues Organ Generation In New Alliance With Japan Partners

Mon, 04/08/2019 - 9:36pm

Sumitomo Dainippon Pharma has entered into a new alliance with a group of academic and venture partners in Japan to...

      Related Stories 

Alnylam Replaces Sanofi Partnership With Second Regeneron Tie-Up For RNAi Drugs

Mon, 04/08/2019 - 1:31pm

Already partnered with Regeneron in NASH, Alnylam unveils a new R&D collaboration in eye, CNS and liver indications, after Alnylam...

      Related Stories 

'Pharma Fireworks': Pipeline Catalysts To Watch Out For In Q2

Mon, 04/08/2019 - 1:21pm

Scrip looks at some the key clinical and regulatory pharma events that will spark attention during the next three months...

      Related Stories 

Rebate Reshuffle: Could Pharma Foot The Bill To Offset Higher Premiums?

Mon, 04/08/2019 - 1:08pm

Bernstein Research analysts said CMS could charge pharmaceutical manufactures a fee to offset increases in insurance premiums anticipated from the...

      Related Stories 

CHART/TABLE: Pipeline Watch: Phase III Starts With Patidegib, Reproxalap

Mon, 04/08/2019 - 2:34am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Finance Watch: NGM Bio Is Second NASH IPO In Two Weeks

Fri, 04/05/2019 - 3:20pm

Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price...

      Related Stories 

Venture Funding Deals: Recent Rounds For Gene-Editing Plays Top $300m

Fri, 04/05/2019 - 11:34am

Gene-editing focused start-ups Beam Therapeutics, Gracell, Snipr Biome and Precision Biosciences raised a total of $310m in financings in February...

      Related Stories 

2018 Saw Record Launches, But No Big Splash

Fri, 04/05/2019 - 11:04am

The number of US drug approvals in 2018 was striking, but most of the novel products launched last year are...

      Related Stories 

GSK Forms New Commercial Trade Channel Team In India

Fri, 04/05/2019 - 8:15am

GlaxoSmithKline India has carved out a specialized team with close to 300 personnel to engage with pharmacists. It is seeking...

      Related Stories 

Merrimack Pharma Cutting Jobs Again After Shelving Third Cancer Drug In Year

Fri, 04/05/2019 - 7:56am

Merrimack Pharmaceuticals is ending development of its lead drug MM-310 because of safety concerns, triggering a fresh round of job...

      Related Stories 

No More Deal? Novartis, Amgen Trade Lawsuits Over Aimovig Agreements

Thu, 04/04/2019 - 6:11pm

Novartis wants a federal judge to stop Amgen from terminating the companies' agreements around potential migraine blockbuster Aimovig, in which...

      Related Stories 

Genfit Hopes To Make Case For First-Line Treatment In NASH

Thu, 04/04/2019 - 1:58pm

French company expects Phase III data later in 2019 that will demonstrate elafibranor’s ability to resolve NASH without worsening of...

      Related Stories 

Pages